• Explore /
  • Poster
  • / Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma.

Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma.

Abstract Video & Slides Poster

Authors

null

Alexandra Jackovich

University of Southern California, Los Angeles, CA

Alexandra Jackovich , Barbara J. Gitlitz , Justin Wayne Wong Tiu-lim , Vinay Duddalwar , Kevin George King , Anthony B. El-Khoueiry , Jacob Stephen Thomas , Denice Tsao-Wei , David I. Quinn , Parkash S. Gill , Jorge J. Nieva

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03049618

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 6016)

DOI

10.1200/JCO.2021.39.15_suppl.6016

Abstract #

6016

Abstract Disclosures

Similar Posters

First Author: Benjamin Philip Levy

Poster

2017 ASCO Annual Meeting

A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.

A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.

First Author: Linda R. Duska

First Author: Li-Yuan Bai

First Author: Timothy Jay Price